Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
X Yin, H Liao, H Yun, N Lin, S Li, Y Xiang… - Seminars in cancer biology, 2022 - Elsevier
Lung cancer accounts for the main proportion of malignancy-related deaths and most
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …
Liquid biopsies, novel approaches and future directions
A Armakolas, M Kotsari, J Koskinas - Cancers, 2023 - mdpi.com
Simple Summary The gold standard for detecting cancer and profiling tumors is tissue
biopsies. Despite this, tissue biopsies have been associated with many limitations leading to …
biopsies. Despite this, tissue biopsies have been associated with many limitations leading to …
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
TA Yap, E Fontana, EK Lee, DR Spigel, M Højgaard… - Nature medicine, 2023 - nature.com
Predictive biomarkers of response are essential to effectively guide targeted cancer
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
J Li, Z Xiao, D Wang, L Jia, S Nie, X Zeng, W Hu - Molecular Cancer, 2023 - Springer
Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …
Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial …
T Powles, ZJ Assaf, V Degaonkar, P Grivas, M Hussain… - European urology, 2024 - Elsevier
Abstract Background Interim results from IMvigor010 showed an overall survival (OS) benefit
for adjuvant atezolizumab (anti–PD-L1) versus observation in patients with circulating tumor …
for adjuvant atezolizumab (anti–PD-L1) versus observation in patients with circulating tumor …
[HTML][HTML] Regulatory implications of ctDNA in immuno-oncology for solid tumors
PJ Vellanki, S Ghosh, A Pathak, MJ Fusco… - … for ImmunoTherapy of …, 2023 - ncbi.nlm.nih.gov
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …
minimally invasive approach for the diagnosis and management of patients with cancer and …
[HTML][HTML] Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
P Vryza, T Fischer, E Mistakidi, A Zaravinos - Translational Oncology, 2023 - Elsevier
Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in
lung cancer management, providing first-time improvements in patient response, prognosis …
lung cancer management, providing first-time improvements in patient response, prognosis …
Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC
J Wu, Z Liu, T Huang, Y Wang, MM Song… - Molecular …, 2023 - Wiley Online Library
Brain metastasis (BM) genetically diverges from the primary tumor in non‐small‐cell lung
cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the …
cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the …
Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer
R Zhang, J Zang, D Jin, F Xie, A Shahatiaili, G Wu… - Clinical Cancer …, 2023 - AACR
Purpose: Bladder preservation is a viable option for some patients with muscle-invasive
bladder cancer (MIBC), but an effective noninvasive biomarker test to accurately identify …
bladder cancer (MIBC), but an effective noninvasive biomarker test to accurately identify …
The role of cell-free DNA in cancer treatment decision making
A Telekes, A Horváth - Cancers, 2022 - mdpi.com
Simple Summary The aim of this review is to evaluate the present status of the use of cell-
free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an …
free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an …